This publication reviews the use of ribociclib, a CDK4/6 inhibitor, for the treatment of HR-positive, HER2 negative metastatic breast cancer. Ribociclib is approved in New Zealand for patients with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, as an initial endocrine-based therapy or following prior endocrine therapy, and is fully subsidised for this use (with Special Authority criteria). OS, HRQOL and safety outcomes from the pivotal phase 3 MONALEESA-2, -3 and -7 trials are summarised. PFS outcomes from a trial of first line ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive disease are also presented. This resource was created with unconditional funding from Novartis NZ Ltd.
Please login below to download this issue (PDF)